French biotech raises $75M for new cell therapy manufacturing tech, Parkinson's treatment
A French cell therapy startup is getting two new offices in opposite parts of the world, and a new CEO to boot as it announces a new round of funding Monday.
Biotech TreeFrog Therapeutics, which is focused on stem cell therapy, closed a $75 million Series B, the company announced. The round brings the company’s total funding to $83 million, and allows them to open up offices in Boston and Kobe, Japan, as it advances its biomimetic C-Stem technology for clinical manufacturing. The US office will start with a staff of around 10 to 15 people, but if all goes well, that will change quickly.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.